Targeted Degradation Technology Based on the Autophagy-Lysosomal Pathway: A Promising Strategy for Treating...

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Biology

Background:

• Targeted protein degradation (TPD) via the autophagy-lysosomal pathway (ALP) is a promising strategy for selectively eliminating disease-related proteins.
• Methods like autophagosome-tethering compounds (ATTEC), autophagy-targeting chimera (AUTAC), and chaperone-mediated autophagy (CMA) targeting chimera are effective against neurodegenerative disorders.
• Accumulation of misfolded proteins in the placenta contributes to preeclampsia (PE), a condition lacking effective treatments.

Purpose of the Study:

• To explore the application of autophagy-mediated TPD technology as a novel therapeutic avenue for preeclampsia.
• To draw parallels between misfolded protein aggregates in neurodegenerative diseases and those implicated in PE.
• To identify potential target proteins in the placenta for ALP-based TPD.

Main Methods:

• Review of existing literature on TPD strategies, ALP, neurodegenerative diseases, and preeclampsia.
• Integration of full-text studies to compare protein aggregation mechanisms.
• Proposal of potential target proteins for placental TPD.

Main Results:

• TPD technologies grounded in ALP offer a pioneering approach for targeted therapy in PE.
• Autophagic degraders can dismantle potential targets contributing to PE.
• Limited current exploration of ALP technology for identifying placental target proteins.

Conclusions:

• Autophagy-mediated TPD presents a novel therapeutic strategy for preeclampsia.
• Further research is needed to identify and validate specific placental targets for TPD.
• This approach holds potential for developing new treatments for preeclampsia.